Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045110 · ClinicalTrials.gov registry record · Phase 1
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
A Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
- 7
- Study locations
NCT00045110 is a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 136 participants, above the 34-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (300% higher). The trial reports 7 study locations across 6 states.
The verdict
NCT00045110, a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
- 7
- Study locations
Study Summary
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG erlotinib hydrochloride
Study Locations (7)
California
- University of California Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
Maryland
- National Cancer Institute Neuro-Oncology Branch - Bethesda
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- University of Pittsburgh - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2002-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045110
The ClinicalTrials.gov registry entry for NCT00045110 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (300% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00045110 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT00045110 about?
NCT00045110 is a clinical study titled "Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma". Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
What is the current status of trial NCT00045110?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2002-08. Estimated completion is 2010-12.
What conditions does trial NCT00045110 study?
This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Adult Anaplastic Astrocytoma.
What interventions are being tested in trial NCT00045110?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00045110?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00045110 being conducted?
This trial has 7 study locations across California, Maryland, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ACTIVE NOT RECRUITING · Phase 1
-
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
COMPLETED · Phase 1
-
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
COMPLETED · Phase 1
-
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.